The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies

Ecstasy (primarily MDMA) is a widely used recreational psychoactive drug that produces euphoria, increased sociability and entactogenic effects by promoting serotonin (5-HT) release and, to a lesser extent, dopamine (DA) release. Preclinical research has long shown that repeated high-dose MDMA exposure can produce marked perturbations of the 5-HT system, and molecular imaging (SPECT and PET) permits in vivo quantification of transporters and receptors to examine whether similar alterations are observable in living animals, non-human primates and humans. Vegting and colleagues set out to review molecular imaging studies that assessed the effects of ecstasy/MDMA on neurotransmitter systems. The review aimed to synthesise findings across small-animal, non-human primate and human PET/SPECT studies, focusing on which targets (for example the serotonin transporter, SERT) show consistent alterations after MDMA exposure and to highlight methodological issues that complicate interpretation, such as polydrug use, dosing and abstinence intervals. The authors emphasise the clinical and public-health relevance of clarifying whether observed imaging changes reflect reversible adaptations versus neurotoxic damage, given both widespread recreational use and renewed interest in therapeutic MDMA.

A PubMed search was performed (search terms not provided in the extracted text) using a PICO framework, and was current to 14 November 2015. The authors increased sensitivity by focusing on terms for MDMA and for imaging techniques. The exact search string and table of search terms are not included in the extracted text. Inclusion criteria required in vivo imaging findings on neurotransmitter systems and either a control group that was MDMA‑naive or a serial design with a baseline measurement taken in an MDMA‑naive state. Exclusion criteria were case reports or reviews, studies that administered a single MDMA challenge, and re-analyses of previously published data. After screening, 33 studies met these criteria. Data extraction recorded the receptor/transporter target, sample sizes and key characteristics of participants or animals, the radiotracer used, amount/timing of MDMA exposure, minimal abstinence intervals and reported outcomes. The authors extracted P values (preferably corrected for multiple comparisons) and calculated percentage changes in tracer binding when means and standard deviations were reported. They also computed effect sizes using Cohen's d (difference between group means divided by pooled standard deviation) to estimate magnitude of group differences. Specifics on study quality assessment or risk-of-bias tools are not described in the extracted text.

Thirty-three studies were included and all examined either the serotonergic (5-HT) or dopaminergic (DA) systems. The review covers measures of 5-HT synthesis, the serotonin transporter (SERT), 5-HT2A and 5-HT1A receptors, the vesicular monoamine transporter (VMAT) in 5-HT- and DA-rich regions, DA D2/3 receptors and release, the dopamine transporter (DAT), and aromatic L‑amino acid decarboxylase activity ([18F]DOPA PET). 5-HT synthesis: Only one human PET study using alpha-[11C]-methyl-L-tryptophan ([11C]AMT) was included. Whole-brain analysis showed reduced 5-HT synthesis across large forebrain regions in MDMA polydrug users versus polydrug-using controls, with increased uptake in brainstem/periaqueductal grey and some lateral prefrontal and temporal areas. Region-of-interest analyses found a significant increase in raphe nuclei synthesis in female MDMA users (raphe P = 0.01, ES = 1.43) and a significant decrease in the precentral gyrus in male users (P = 0.029, ES = -1.14). Serotonin transporter (SERT): Twenty-seven studies addressed SERT (11 in animals, 16 in humans). The majority reported reduced SERT binding after MDMA. In human studies 14 of 16 reported significant SERT reductions, most pronounced in cortical regions such as occipital cortex (six of ten studies reporting occipital measures found greatest decreases; human effect sizes ranged roughly -0.05 to -2.17). Animal studies also showed decreases, with larger effect sizes reported (animal ES range cited -0.38 to -20.03 in the extracted text). Methodological heterogeneity included differing radiotracers ([123I]β-CIT for SPECT versus PET tracers such as [11C]DASB or [18F]ADAM), variations in analysis methods (simple ratio vs kinetic modelling), and variable abstinence windows. 5-HT2A receptor: Five human studies examined 5-HT2A binding; findings were inconsistent. Three studies reported increased cortical 5-HT2A binding in MDMA users (abstinence ranging 2.0–169.8 weeks; ES 0.14–1.84), whereas two reported decreased binding (abstinence 1.6–36.9 weeks). One SPECT study reported lower cortical 5-HT2A binding in recent users and a positive correlation between 5-HT2A binding and duration of abstinence (P < 0.01), but other studies did not replicate a consistent abstinence–binding relationship. 5-HT1A receptor and serotonergic VMAT: One animal study of 5-HT1A receptor binding showed no significant change after MDMA. One non-human primate study examined VMAT in midline 5-HT-rich structures and reported no significant differences between self-administering and control animals. Dopamine system (D2/3 receptors, DA release, DAT, decarboxylase activity, dopaminergic VMAT): Findings were generally negative for MDMA effects on the DA system in humans. One human study reported lower baseline striatal D2/3 binding and smaller task-induced DA release in ex-MDMA users versus controls, but differences were not statistically significant (ES 0.07–0.32). Three human DAT studies yielded mixed results: two non-significant, and one study reported a 13% increase in striatal binding ratios in MDMA users versus controls (P = 0.045, ES = 2.92), though that study included amphetamine users and subgroup analyses implicated amphetamines rather than MDMA in DAT changes. A single [18F]DOPA study found increased decarboxylase activity in ex-MDMA users versus drug‑naive controls in caudate/putamen/ventral striatum (putamen P = 0.021, ES = 1.10), but this difference was absent when compared with polydrug-using controls. One animal VMAT study in basal ganglia reported no differences. Recovery and cognitive findings: Several longitudinal and cross-sectional studies reported partial or full recovery of SERT binding with prolonged abstinence; some studies found SERT normalisation after approximately one year, and positive correlations between SERT binding and duration of abstinence were reported in multiple datasets. However, recovery of SERT binding did not uniformly coincide with recovery of cognitive measures: some studies reported persistent verbal and visuospatial memory deficits despite normalised SERT binding, whereas other methodologically rigorous studies found little evidence for cognitive impairment. Effect sizes and significance varied across studies and were often influenced by choice of control group and polydrug exposure.

Vegting and colleagues interpret the imaging literature as showing a robust pattern of reduced SERT binding after heavy MDMA use or high‑dose MDMA administration, across animal and human studies, while findings for 5-HT2A receptors are inconsistent and most human studies find no convincing, consistent effect on the dopamine system. They highlight that animal studies typically used higher and more frequent dosing regimens (often intraperitoneal, e.g. twice daily for several days) and therefore produced larger effect sizes than human studies; interspecies differences in metabolism and dose scaling complicate direct translation. The authors discuss several methodological factors that limit causal inference. Common issues include small sample sizes (animal N range 1–26; human studies 14–116), variable and sometimes short abstinence windows (some studies used only 1 week), polydrug use among human participants and heterogeneous radiotracers and analysis methods (SPECT [123I]β-CIT versus PET [11C]DASB/[18F]ADAM, ratio methods versus kinetic modelling). They note that not all studies corrected for multiple comparisons and that limited spatial resolution (especially of clinical SPECT) can bias quantification in small structures. Vegting and colleagues outline alternative explanations for reduced receptor/transporter binding measured by PET/SPECT: true loss of neurons (neurotoxicity), down-regulation or internalisation of transporters (reducing membrane availability), decreased protein expression, or competition from increased endogenous neurotransmitter release. They recommend translational animal work employing techniques such as electron microscopy, high-performance liquid chromatography, and determination of Bmax and Kd to distinguish these mechanisms and to validate imaging markers as indicators of neurotoxicity. The authors also emphasise the need for appropriately matched polydrug control groups and for animal models that better mimic human patterns of voluntary MDMA use; self-administration studies showed smaller effect sizes than passive high-dose regimens. Specific open questions flagged by the authors include the role of age at first exposure (limited evidence suggests earlier exposure may be associated with greater midbrain SERT reductions), possible sex differences (findings are mixed), and whether recovery of SERT binding reflects restored neuronal function or compensatory processes such as sprouting or down‑regulated neurotransmitter release. Given both recreational prevalence and emerging therapeutic applications of MDMA, the authors call for larger, carefully controlled translational studies to resolve whether imaging changes represent persistent neurotoxic damage or reversible adaptations.

The review concludes that imaging studies consistently report loss of SERT binding associated with heavy MDMA use or high‑dose MDMA administration, but available data do not definitively demonstrate that these imaging changes represent serotonergic neurotoxicity in humans. Evidence for alterations in 5-HT2A receptors is inconsistent, and most human molecular imaging studies do not show clear effects of MDMA on the dopamine system. The authors recommend large translational studies and additional animal and human work to determine the causes of binding alterations (for example Bmax/Kd studies, HPLC for neurotransmitter concentrations, electron microscopy), to clarify the influence of age at first use and sex, and to distinguish reversible adaptations from irreversible neuronal damage.